A Phase 2 interventional study of pemetrexed in Rectal Neoplasms, sponsored by Eli Lilly and Company. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-07-21.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Rectal Neoplasms with a site in Sweden — 15 open to participants now, 22 under way, 4 of them phase 3. Rectal Neoplasms · Sweden.
Among the 64 studies in Rectal Neoplasms with a site in Sweden, this one is the 33rd largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2006, is one of 5 in phase 2, and was the 7th registered.
2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.
Browse Rectal Neoplasms studies →15 of the 64 studies in Rectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Sweden, United States, Canada and 6 more countries
Ages 18+
Alexander Valdman · Sites in Sweden
Ages 18+
NanoEcho AB · Sites in Sweden
Ages 18–99 · Healthy volunteers
Skane University Hospital · Sites in Sweden
Ages 18+
Region Skane · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 11 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 65 across 1,753 interventional studies indexed under Rectal Neoplasms.
Median enrollment 233 across the 40 interventional studies, 142 across the 23 observational. Of the 34 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 64 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 5 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Neoplasms with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02945566Phase 3University of BirminghamCan we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? | 2027-08 |
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT02669992Karolinska University HospitalLoop Ileostomy Closure:Stapled or Hand-sewn Anastomoses? Suture or Mesh Closure of the Stoma Site? | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 64 studies in Rectal Neoplasms with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to help answer the following research questions:
If the study drug Pemetrexed can help patients with rectal cancer; If molecular biological parameters are correlated respectively changing due to cytotoxic treatment with Pemetrexed; To evaluate adverse events
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed
500 mg/m2, intravenous (IV), every 21 days x 3 cycles
Also known as: LY231514, Alimta
Feasibility of Pemetrexed Prior to Surgery
Feasibility was defined as the ability to receive the total planned dose of Pemetrexed administered over a period of no more than 9 weeks permitting scheduling conflict. A ±5 percent variance in the calculated total dose was allowed.
Time frame: 3 cycles (21-day cycles)
Pathological Complete Response (pCR)
Pathological complete response was defined as the absence of any tumor cells.
Time frame: surgery following 3 cycles (21-day cycles) of chemotherapy
Number of Participants With Complete Tumor Resection
Time frame: surgery following 3 cycles (21-day cycles) of chemotherapy
Number of Participants Receiving Sphincter Saving Surgery
Time frame: surgery following 3 cycles (21-day cycles) of chemotherapy
| Milestone | Pemetrexed |
|---|---|
| Started | 37 |
| Completed | 37 |
| Not completed | 0 |
Feasibility was defined as the ability to receive the total planned dose of Pemetrexed administered over a period of no more than 9 weeks permitting scheduling conflict. A ±5 percent variance in the calculated total dose was allowed.
| participants | Pemetrexed |
|---|---|
| Feasibility - Yes | 33 |
| Feasibility - No | 4 |
Pathological complete response was defined as the absence of any tumor cells.
| participants | Pemetrexed |
|---|---|
| Complete Response - Yes | 0 |
| Complete Response - No | 1 |
| Complete Response - Not Determined | 36 |
| participants | Pemetrexed |
|---|---|
| Number of Participants With Complete Tumor Resection | 37 |
| participants | Pemetrexed |
|---|---|
| Surgery - Yes | 25 |
| Surgery - No | 12 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed | — | — | — |
| Event | Pemetrexed |
|---|---|
| IleusGastrointestinal disorders | 5/37 |
| Wound complicationInjury, poisoning and procedural complications | 3/37 |
| DiarrhoeaGastrointestinal disorders | 2/37 |
| Atrial fibrillationCardiac disorders | 1/37 |
| Myocardial ischaemiaCardiac disorders | 1/37 |
| Abdominal painGastrointestinal disorders | 1/37 |
| VomitingGastrointestinal disorders | 1/37 |
| PyrexiaGeneral disorders | 1/37 |
| Anorectal infectionInfections and infestations | 1/37 |
| InfectionInfections and infestations | 1/37 |
| Event | Pemetrexed |
|---|---|
| FatigueGeneral disorders | 23/37 |
| NauseaGastrointestinal disorders | 18/37 |
| Lacrimation increasedEye disorders | 17/37 |
| UrticariaSkin and subcutaneous tissue disorders | 9/37 |
| DiarrhoeaGastrointestinal disorders | 7/37 |
| Buttock painMusculoskeletal and connective tissue disorders | 7/37 |
| HeadacheNervous system disorders | 7/37 |
| Dry mouthGastrointestinal disorders | 6/37 |
| PyrexiaGeneral disorders | 6/37 |
| Mucosal inflammationGeneral disorders | 4/37 |
| Age Continuous(years) | Pemetrexed |
|---|---|
| Mean | 60.3 ± 11.5 |
| Sex: Female, Male(Participants) | Pemetrexed |
|---|---|
| Female | 11 |
| Male | 26 |
| Region of Enrollment(participants) | Pemetrexed |
|---|---|
| Sweden | 37 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Pemetrexed |
|---|---|
| 0 - Fully Active | 37 |
| 1 - Ambulatory, Restricted Strenuous Activity | 0 |
| 2 - Ambulatory, No Work Activities | 0 |
| 3 - Partially Confined to Bed, Limited Self Care | 0 |
| 4 - Completely Disabled | 0 |
| Histopathological Diagnosis(participants) | Pemetrexed |
|---|---|
| G1 - Well-Differentiated | 3 |
| G2 - Moderately Differentiated | 25 |
| G3 - Poorly Differentiated | 3 |
| Not Applicable | 4 |
| Unspecified | 2 |
| Race/Ethnicity(participants) | Pemetrexed |
|---|---|
| Caucasian | 36 |
| East Asian | 1 |
| Blood Pressure(mm Hg) | Pemetrexed |
|---|---|
| Systolic Blood Pressure | 136.5 ± 18.4 |
| Diastolic Blood Pressure | 77.6 ± 9.1 |
| Body Height(centimeters) | Pemetrexed |
|---|---|
| Mean | 173.4 ± 9.4 |
4 further baseline measures are reported on the registry.
The record gives a start of Jun 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed